EUVIMEDEUVIMED entdecken
Crossref

Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy

Martin P Hosking, Soheila Shirinbak, Kyla Omilusik, Shilpi Chandra, Mika K Kaneko, Angela Gentile, Susumu Yamamoto, Bishwas Shrestha, Joy Grant, Megan Boyett, Demetrio Cardenas, Hannah Keegan und 15 weitere

Cell Stem Cell · 2025-07 · 32 (7) · 1087-1101.e4

DOI: 10.1016/j.stem.2025.05.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Stem Cell, 2025-07. Verfasst von Martin P Hosking und 26 weiteren Autor:innen. Beteiligte Einrichtung: Fate Therapeutics, Inc., San Diego, CA, USA. Electronic address: martin.hosking@fatetherapeutics.com. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Induced Pluripotent Stem Cells, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 83 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesInduced Pluripotent Stem CellsReceptors, Chimeric AntigenImmunotherapy, AdoptiveNeoplasmsT-LymphocytesHumansAnimalsMiceFemaleCell Line, TumorMice, Inbred NOD

Stichwörter der Autor:innen

CAR THER2TGF-βantibody-dependent cellular cytotoxicityiPSCsolid tumortrafficking

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, Chimeric AntigenERBB2 protein, human

Autor:innen und Institutionen

  • Fate Therapeutics, Inc., San Diego, CA, USA. Electronic address: martin.hosking@fatetherapeutics.com.
  • Fate Therapeutics, Inc., San Diego, CA, USA.
  • Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.
  • Minase Research Institute, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
  • Institute for Protein Research, Osaka University, 3-2, Yamadaoka, Suita 565-0871, Osaka, Japan.
  • Fate Therapeutics, Inc., San Diego, CA, USA. Electronic address: bob.valamehr@fatetherapeutics.com.

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Hosking, M. P., Shirinbak, S., Omilusik, K., Chandra, S., Kaneko, M. K., Gentile, A., Yamamoto, S., Shrestha, B., Grant, J., Boyett, M., Cardenas, D., Keegan, H., Ibitokou, S., Pavon, C., Mizoguchi, T., Ihara, T., Nakayama, D., Abujarour, R., Lee, T. T., …, & Valamehr, B. (2025). Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy. Cell Stem Cell, 32(7), 1087-1101.e4. https://doi.org/10.1016/j.stem.2025.05.007

Vancouver

Hosking MP, Shirinbak S, Omilusik K, Chandra S, Kaneko MK, Gentile A, et al. Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy. Cell Stem Cell. 2025;32(7):1087-1101.e4. doi:10.1016/j.stem.2025.05.007

BibTeX
@article{Hosking2025,
  author = {Hosking, Martin P and Shirinbak, Soheila and Omilusik, Kyla and Chandra, Shilpi and Kaneko, Mika K and Gentile, Angela and Yamamoto, Susumu and Shrestha, Bishwas and Grant, Joy and Boyett, Megan and Cardenas, Demetrio and Keegan, Hannah and Ibitokou, Samad and Pavon, Carolina and Mizoguchi, Takahiro and Ihara, Tatsuya and Nakayama, Daisuke and Abujarour, Ramzey and Lee, Tom T and Clarke, Raedun and Goodridge, Jode and Peralta, Eigen and Maeda, Tatsuo and Takagi, Junichi and Arimori, Takao and Kato, Yukinari and Valamehr, Bahram},
  title = {Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy},
  journal = {Cell Stem Cell},
  year = {2025},
  volume = {32},
  number = {7},
  pages = {1087--1101.e4},
  doi = {10.1016/j.stem.2025.05.007}
}
Kostenlos starten →